Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 7, 2009, Pages 1113-1120

  Squitieri, Ferdinando ^a   Orobello, Sara ^a   Cannella, Milena ^a   Martino, Tiziana ^a   Romanelli, Pantaleo ^a   Giovacchini, Giampiero ^b   Frati, Luigi ^c   Mansi, Luigi ^d   Ciarmiello, Andrea ^b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Brain derived neurotrophic factor; FDG PET scan; Neurotrophins; Transforming growth factor; Volumetric MRI

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUTAMIC ACID; NEUROTROPHIN; RILUZOLE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MALE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RATING SCALE; SCORING SYSTEM; SINGLE BLIND PROCEDURE;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; HUNTINGTON DISEASE; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PLACEBOS; POSITRON-EMISSION TOMOGRAPHY; RILUZOLE;

EID: 67349146480     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1103-3     Document Type: Article

References (34)

1. JP Vonsattel RH Myers TJ Stevens RJ Ferrante ED Bird EP Richardson Jr 1985 Neuropathological classification of Huntington's disease J Neuropathol Exp Neurol 44 559 577 (Pubitemid 16196286)
2. A Ciarmiello M Cannella S Lastoria M Simonelli L Frati DC Rubinsztein 2006 Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease J Nucl Med 47 215 222 (Pubitemid 46780885)
3. HD Rosas DH Salat SY Lee AK Zaleta V Pappu B Fischl 2008 Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity Brain 131 1057 1068
4. MF Beal NW Kowall DW Ellison MF Mazurek KJ Swartz JB Martin 1986 Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid Nature 321 168 171 (Pubitemid 16022019)
5. LR Gauthier BC Charrin M Borrell-Pages JP Dompierre H Rangone FP Cordelières 2004 Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules Cell 118 127 138 (Pubitemid 38902819)
6. A Ciammola J Sassone M Cannella S Calza B Poletti L Frati 2007 Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients Am J Med Genet B Neuropsychiatr Genet 144B 574 577 (Pubitemid 46983172)
7. C Zuccato A Ciammola D Rigamonti BR Leavitt D Goffredo L Conti 2001 Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease Science 293 493 498 (Pubitemid 32679077)
8. RT Schaub D Anders G Golz K Göhringer R Hellweg 2002 Serum nerve growth factor concentration and its role in the preclinical stage of dementia Am J Psychiatry 159 1227 1229 (Pubitemid 34743266)
9. I Tesseur K Zou L Esposito F Bard E Berber JV Can 2006 Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology J Clin Invest 116 3060 3069 (Pubitemid 44684491)
10. E Pérez-Navarro E Arenas J Reiriz N Calvo J Alberch 1996 Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage Neuroscience 75 345 352 (Pubitemid 26361327)
11. V Bruno G Battaglia G Casabona A Copani F Caciagli F Nicoletti 1998 Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta J Neurosci 18 9594 9600 (Pubitemid 28543740)
12. SE Browne MF Beal 2006 Oxidative damage in Huntington's disease pathogenesis Antioxid Redox Signal 8 2061 2073 (Pubitemid 46489631)
13. A Hodges AD Strand AK Aragaki A Kuhn T Sengstag G Hughes 2006 Regional and cellular gene expression changes in human Huntington's disease brain Hum Mol Genet 15 965 977 (Pubitemid 43338237)
14. A Feigin MF Ghilardi C Huang Y Ma M Carbon M Guttman 2006 Preclinical Huntington's disease: compensatory brain responses during learning Ann Neurol 59 53 59 (Pubitemid 43042871)
15. F Squitieri A Ciarmiello S Di Donato L Frati 2006 The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction Eur J Neurol 13 408 415
16. F Giorgini P Guidetti Q Nguyen SC Bennett PJ Muchowski 2005 A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease Nat Genet 37 526 531 (Pubitemid 40617282)
17. F Squitieri A Berardelli E Nargi B Castellotti C Mariotti M Cannella 2000 Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis Clin Genet 58 50 56 (Pubitemid 30468429)
18. A Bergerot PJ Shortland P Anand SP Hunt T Carlstedt 2004 Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury Exp Neurol 187 359 366 (Pubitemid 38610282)
19. R Katoh-Semba T Asano H Ueda R Morishita IK Takeuchi Y Inaguma 2002 Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus FASEB J 16 1328 1330
20. F Squitieri A Ciammola C Colonnese A Ciarmiello 2008 Neuroprotective effects of riluzole in Huntington's disease Eur J Nucl Med Mol Imaging 35 221 222 (Pubitemid 50001344)
21. F Squitieri C Gellera M Cannella C Mariotti G Cislaghi DC Rubinsztein 2003 Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course Brain 126 946 955 (Pubitemid 36372991)
22. Huntington Study Group 1996 The Unified Huntington's Disease Rating Scale: reliability and consistency Mov Disord 11 136 142
23. B Alfano A Brunetti EM Covelli M Quarantelli MR Panico A Ciarmiello 1997 Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach Magn Reson Med 37 84 93 (Pubitemid 27008834)
24. M Quarantelli K Berkouk A Prinster B Landeau C Svarer L Balkay 2004 Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction J Nucl M d 45 192 201 (Pubitemid 47618636)
25. HW Muller-Gartner JM Links JL Prince RN Bryan E [tmp] McVeigh JP Leal 1992 Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects J Cereb Blood Flow Metab 12 571 583
26. OG Rousset Y Ma AC Evans 1998 Correction for partial volume effects in PET: principle and validation J Nucl Med 39 904 911 (Pubitemid 28216748)
27. Research Imaging Center, University of Texas Health Science Center at San Antonio. Talairach Daemon Client download. http://www.talairach.org/client. html. Accessed 26 Feb 2009.
28. GB Landwehrmeyer B Dubois JG de Yébenes B Kremer W Gaus PH Kraus 2007 Riluzole in Huntington's disease: A 3-year, randomized controlled study Ann Neurol 62 262 272 (Pubitemid 47525402)
29. KM Giehl A Schütte P Mestres Q Yan 1998 The survival-promoting effect of glial cell line-derived neurotrophic factor on axotomized corticospinal neurons in vivo is mediated by an endogenous brain-derived neurotrophic factor mechanism J Neurosci 18 7351 7360 (Pubitemid 28425819)
30. K Krieglstein P Henheik L Farkas J Jaszai D Galter K Krohn 1998 Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons J Neurosci 18 9822 9834 (Pubitemid 28543761)
31. S Paradiso BM Turner JS Paulsen R Jorge LL Ponto RG Robinson 2008 Neural bases of dysphoria in early Huntington's disease Psychiatry Res 162 73 87 (Pubitemid 50009836)
32. SM Lehto J Kuikka T Tolmunen M Valkonen-Korhonen M Joensuu PI Saarinen 2008 Temporal cortex dopamine D2/3 receptor binding in major depression Psychiatry Clin Neurosci 62 345 348 (Pubitemid 351832322)
33. F Squitieri M Cannella L Frati 2008 Molecular medicine: predicting and preventing Huntington's disease Neurol Sci 29 205 207
34. F Squitieri M Cannella M Simonelli J Sassone T Martino E Venditti 2009 Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease CNS Neurosci Ther 15 1 11